Cargando…

Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab

There is little evidence regarding the maintenance of long-term clinical remission by adalimumab (ADA) therapy in Crohn's disease (CD) patients naïve to anti-tumor necrosis factor treatment (naïve CD patients), since most CD patients are treated with ADA after infliximab (IFX) therapy. The long...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mizoshita, Tsutomu, Tanida, Satoshi, Ozeki, Keiji, Katano, Takahito, Shimura, Takaya, Mori, Yoshinori, Kubota, Eiji, Kataoka, Hiromi, Kamiya, Takeshi, Joh, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939671/ https://www.ncbi.nlm.nih.gov/pubmed/27462198 http://dx.doi.org/10.1159/000445105

Ejemplares similares

Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement
por: Mizoshita, Tsutomu, et al.
Publicado: (2014)

Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet’s Disease: Eight Consecutive Cases
por: Tanida, Satoshi, et al.
Publicado: (2016)

Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy
por: Mizoshita, Tsutomu, et al.
Publicado: (2017)

Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2015)

The First Case of Biological Therapy Discontinuation After a Complete Remission Induced by Maintenance Therapy With Adalimumab for Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2015)

Organizing Pneumonia in a Patient with Quiescent Crohn's Disease
por: Tanida, Satoshi, et al.
Publicado: (2016)

Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn's Disease
por: Ozeki, Keiji, et al.
Publicado: (2012)

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
por: Suzuki, Taketo, et al.
Publicado: (2019)

Managing refractory Crohn’s disease: challenges and solutions
por: Tanida, Satoshi, et al.
Publicado: (2015)

Induction Therapy With a Combination of Weekly Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Ulcerative Colitis and Failure of Conventional Agents, Biologics and Janus Kinase Inhibitor
por: Tanida, Satoshi, et al.
Publicado: (2023)

Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus
por: Mizoshita, Tsutomu, et al.
Publicado: (2013)

A Complicated Case of Tacrolimus-Induced Rapid Remission after Cesarean Section in the Early Third Trimester for Refractory Severe Ulcerative Colitis Flaring in the Initial Period of Gestation
por: Mizushima, Takashi, et al.
Publicado: (2011)

Telmisartan Inhibits Cell Proliferation by Blocking Nuclear Translocation of ProHB-EGF C-Terminal Fragment in Colon Cancer Cells
por: Ozeki, Keiji, et al.
Publicado: (2013)

Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2020)

The efficacy of maintenance therapy after remission induction with tacrolimus in ulcerative colitis with and without previous tumor necrosis factor‐α inhibitor
por: Suzuki, Taketo, et al.
Publicado: (2019)

Involvement of oxidative stress and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in inflammatory bowel disease
por: Tanida, Satoshi, et al.
Publicado: (2011)

Mechanisms of Cisplatin-Induced Apoptosis and of Cisplatin Sensitivity: Potential of BIN1 to Act as a Potent Predictor of Cisplatin Sensitivity in Gastric Cancer Treatment
por: Tanida, Satoshi, et al.
Publicado: (2012)

Therapeutic Effects of Biobran, Modified Arabinoxylan Rice Bran, in Improving Symptoms of Diarrhea Predominant or Mixed Type Irritable Bowel Syndrome: A Pilot, Randomized Controlled Study
por: Kamiya, Takeshi, et al.
Publicado: (2014)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Expression and subcellular localization of AT motif binding factor 1 in colon tumours
por: Kataoka, Hiromi, et al.
Publicado: (2017)

Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity
por: Song, Christine H, et al.
Publicado: (2012)

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn’s Disease: Results of the PYRAMID Registry
por: Loftus, Edward V, et al.
Publicado: (2019)

Pyostomatitis Vegetans and Pyoderma Gangrenosum after Total Colectomy
por: Ozeki, Keiji, et al.
Publicado: (2022)

Adalimumab in Crohn’s disease
por: Van Assche, Gert, et al.
Publicado: (2007)

Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
por: Jung, Yoon Suk, et al.
Publicado: (2021)

Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease
por: Carlsen, Arne, et al.
Publicado: (2018)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020)

Urinary Cysteine-Rich Protein 61 and Trefoil Factor 3 as Diagnostic Biomarkers for Colorectal Cancer()
por: Shimura, Takaya, et al.
Publicado: (2019)

Combination Therapy With Ustekinumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2021)

Corrigendum to: Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
Publicado: (2021)

Nuclear translocation of the cytoplasmic domain of HB-EGF induces gastric cancer invasion
por: Shimura, Takaya, et al.
Publicado: (2012)

Adalimumab for the treatment of Crohn’s disease
por: Cassinotti, Andrea, et al.
Publicado: (2008)

Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study
por: Eng, Grith P., et al.
Publicado: (2015)

Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn’s Disease
por: Orts, Beatriz, et al.
Publicado: (2022)

Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis
por: Yang, Hua-Hua, et al.
Publicado: (2022)

Determination of lower cut‐off levels of adalimumab associated with biochemical remission in Crohn's disease
por: Carlsen, Arne, et al.
Publicado: (2019)

Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis
por: Yin, Juntao, et al.
Publicado: (2022)

Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
por: Lee, Yong Il, et al.
Publicado: (2021)

Novel and Simple Criteria for Predicting Mortality of Peptic Ulcer Disease
por: Iwasaki, Hiroyasu, et al.
Publicado: (2021)

Adalimumab and Infliximab in Crohn’s disease - real life data from a national retrospective cohort study
por: PREDA, C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vk9jk10s1p73qjojp6bipf3do3